| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 24, 2002
From the University of Virginia, Departments of Neurology and Health Evaluation Sciences (B.B.W.), Charlottesville, Va; Stroke Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Md (B.B.W., S.A., P.A.N., T.L.H., T.J.D.); Massachusetts General Hospital, Departments of Neurology and Neuroradiology, Boston (R.H.A.); and National Naval Medical Center, Bethesda, Md (T.L.H., T.J.D.). * To whom correspondence should be addressed. E-mail: TJDeGraba{at}bethesda.med.navy.mil.
Background and Purpose--Inflammation plays an important role in the development of atherosclerosis. The gene for the counterinflammatory cytokine interleukin-1 receptor antagonist (IL-1ra) is polymorphic, and high frequencies of allele 2 have been found to be associated with other inflammatory diseases. This study examined the association of allele and carrier frequencies of the IL-1ra gene with the presence of carotid atherosclerosis and plaque symptomaticity. Methods--A total of 328 subjects identified as having carotid atherosclerosis or no atherosclerosis (controls) participated. Blood was obtained for DNA determination. Results--Frequency of allele 2 was significantly greater in patients with atherosclerosis compared with nonatherosclerotic subjects. No difference was seen between symptomatic and asymptomatic atherosclerosis patients. Noncarriage of allele 2 was associated with reduced likelihood of atherosclerosis (odds ratio [OR], 0.44; 95% CI, 0.27 to 0.71). The homozygous carrier state for allele 2 was associated with greater likelihood of atherosclerosis (unadjusted OR, 7.30; 95% CI, 2.31 to 22.94; adjusted OR, 13.78; 95% CI, 1.94 to 97.9). A gene-dose effect was detected. Conclusions--These data suggest that allele 2 of the IL-1ra gene represents a susceptibility factor in the development of carotid atherosclerosis. Further investigation appears warranted.
Accepted on September 26, 2002
Interleukin-1 Receptor Antagonist Gene Polymorphisms in Carotid Atherosclerosis
Bradford B. Worrall MD, MSc;
This article has been cited by other articles:
![]() |
B. B. Worrall, T. G. Brott, R. D. Brown Jr, W. M. Brown, S. S. Rich, S. Arepalli, F. Wavrant-De Vrieze, J. Duckworth, A. B. Singleton, J. Hardy, et al. IL1RN VNTR Polymorphism in Ischemic Stroke: Analysis in 3 Populations Stroke, April 1, 2007; 38(4): 1189 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Hadjigeorgiou, K. Paterakis, E. Dardiotis, M. Dardioti, K. Aggelakis, A. Tasiou, G. Xiromerisiou, A. Komnos, E. Zintzaras, N. Scarmeas, et al. IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury Neurology, October 11, 2005; 65(7): 1077 - 1082. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Merhi-Soussi, B. R. Kwak, D. Magne, C. Chadjichristos, M. Berti, G. Pelli, R. W. James, F. Mach, and C. Gabay Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice Cardiovasc Res, June 1, 2005; 66(3): 583 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. DeGraba Immunogenetic Susceptibility of Atherosclerotic Stroke: Implications on Current and Future Treatment of Vascular Inflammation Stroke, November 1, 2004; 35(11_suppl_1): 2712 - 2719. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Manolio, E. Boerwinkle, C. J. O'Donnell, and A. F. Wilson Genetics of Ultrasonographic Carotid Atherosclerosis Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1567 - 1577. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |